RT  - European Journal of Gynaecological Oncology
ID  - 10.12892/ejgo2709.2015
T1  - Surgical Stage I high-grade ovarian cancer: is adjuvant chemotherapy warranted?
A1  - Y. Segev
A1  - N. Ismiil
A1  - R. McVey
A1  - A. Covens
K1  - Ovarian cancer; Surgical staging; Adjuvant chemotherapy; High grade; Early stage.
YR  - 2015
SP  - 633
AB  - <p><i>Objective: </i>To review the results of patients with high-grade Stage I ovarian cancer managed without adjuvant treatment. <i>Materials</i><i> </i><i>and Methods: </i>A retrospective chart review identified patients with newly diagnosed Stage I high-grade ovarian cancer, who underwent comprehensive surgical staging. <i>Results: </i>Thirty-three patients with FIGO surgical Stage I high-grade ovarian cancer were identified. After a median follow-up of 40 months, nine patients (27%) recurred. The median time to recurrence was 19 months. Of the nine patients with recurrences, four (44%) are alive with disease, three (33%) patients have no evidence of disease, and two have died of disease (22%). The two- and five-year overall survival is 100% and 90%, respectively. <i>Conclusions: </i>It would appear the recurrence rates of Stage I high risk epithelial ovarian cancer completely staged, without adjuvant treatment are comparable to those of treatment arms reported in the literature. A proportion of these patients can be salvaged at recurrence, yielding a high overall survival.</p>